Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

Company Overview - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases [3] - The company aims to improve patient outcomes through its science-driven approach and deep R&D expertise [3] Leadership Appointment - Kieron Wesson, PhD, has been appointed as Vice President, Head of Chemistry Manufacturing Controls (CMC) at Aligos, effective immediately [1] - Dr. Wesson brings over 20 years of experience in pharmaceutical development, having previously held leadership roles at Kezar Life Sciences and AN2 Therapeutics [2] - His expertise will provide leadership and oversight on all CMC-related matters as Aligos prepares to begin its Phase 2 study of ALG-000184 in mid-2025 [2] Pipeline and Research Focus - Aligos is advancing a purpose-built pipeline targeting high unmet medical needs, including chronic hepatitis B virus infection and metabolic dysfunction-associated steatohepatitis (MASH) [3] - The company is set to initiate a Phase 2 clinical study for its therapeutic candidate ALG-000184 in mid-2025 [2]